2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
94
Leukemia, Myeloid, Chronic-Phase
25
Leukemia
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Gastrointestinal Stromal Tumors
15
Blast Crisis
9
Neoplasms
8
Neoplasm Metastasis
6
Philadelphia Chromosome
4
Myeloproliferative Disorders
4
Melanoma
4
Leukemia, Myeloid
4
Bone Marrow Diseases
4
Recurrence
3
Leukemia, Myeloid, Acute
3
Leukemia, Myeloid, Accelerated Phase
3
Hematologic Diseases
3
Bronchiolitis Obliterans Syndrome
3
Synovitis, Pigmented Villonodular
2
Ovarian Neoplasms
2
Neoplasm, Residual
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Substance Withdrawal Syndrome
1
Sarcoma
1
Retroperitoneal liposarcoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Piebaldism
1
Peritoneal Neoplasms
1
Neurofibromatoses
1
Interventions
salicylhydroxamic acid
1
nilotinib
1
morphine, naltrexone combination
1
Naltrexone
1
Morphine
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Substance Withdrawal Syndrome
×
nilotinib
×
Clear all
NCT04147533
2024-11-26
HALF
Masaryk University
Phase 2
Active not recruiting
150 enrolled